Abstract
Aims and background: No consolidated medical treatment has yet been established for unresectable hepatocellular carcinoma (HCC). A possible interference of hormones in the pathogenesis and cellular growth of HCC has been suggested. Methods: To evaluate the activity and tolerance of progestins in HCC, patients were treated with megestrol acetate orally at a dose of 160 mg daily until progression of disease or grade III-IV toxicity was observed. Results: Eleven patients entered the study and were assessable for response and side effects. Median duration of treatment was 80 days (range 60-150). No major responses were observed, 4 patients had stabilization of disease for at least 2 months, and 7 had progressive disease. Median time to disease progression was 3 months (range 2-5). Three patients required interruption of treatment because of toxicity (2 patients had worsening of concomitant diabetes and 1 patient had gastric bleeding). Conclusions: The results of the present study suggest that hormone therapy with megestrol acetate has no significant role in HCC.
| Original language | English |
|---|---|
| Pages (from-to) | 351-353 |
| Number of pages | 3 |
| Journal | Tumori |
| Volume | 81 |
| Issue number | 5 |
| Publication status | Published - 1995 |
Fingerprint
Keywords
- hepatocellular carcinoma
- megestrol acetate
ASJC Scopus subject areas
- Cancer Research
Cite this
Megestrol acetate in unresectable hepatocellular carcinoma. / Colleoni, M.; Nelli, P.; Vicario, G.; Mastropasqua, G.; Manente, P.
In: Tumori, Vol. 81, No. 5, 1995, p. 351-353.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Megestrol acetate in unresectable hepatocellular carcinoma
AU - Colleoni, M.
AU - Nelli, P.
AU - Vicario, G.
AU - Mastropasqua, G.
AU - Manente, P.
PY - 1995
Y1 - 1995
N2 - Aims and background: No consolidated medical treatment has yet been established for unresectable hepatocellular carcinoma (HCC). A possible interference of hormones in the pathogenesis and cellular growth of HCC has been suggested. Methods: To evaluate the activity and tolerance of progestins in HCC, patients were treated with megestrol acetate orally at a dose of 160 mg daily until progression of disease or grade III-IV toxicity was observed. Results: Eleven patients entered the study and were assessable for response and side effects. Median duration of treatment was 80 days (range 60-150). No major responses were observed, 4 patients had stabilization of disease for at least 2 months, and 7 had progressive disease. Median time to disease progression was 3 months (range 2-5). Three patients required interruption of treatment because of toxicity (2 patients had worsening of concomitant diabetes and 1 patient had gastric bleeding). Conclusions: The results of the present study suggest that hormone therapy with megestrol acetate has no significant role in HCC.
AB - Aims and background: No consolidated medical treatment has yet been established for unresectable hepatocellular carcinoma (HCC). A possible interference of hormones in the pathogenesis and cellular growth of HCC has been suggested. Methods: To evaluate the activity and tolerance of progestins in HCC, patients were treated with megestrol acetate orally at a dose of 160 mg daily until progression of disease or grade III-IV toxicity was observed. Results: Eleven patients entered the study and were assessable for response and side effects. Median duration of treatment was 80 days (range 60-150). No major responses were observed, 4 patients had stabilization of disease for at least 2 months, and 7 had progressive disease. Median time to disease progression was 3 months (range 2-5). Three patients required interruption of treatment because of toxicity (2 patients had worsening of concomitant diabetes and 1 patient had gastric bleeding). Conclusions: The results of the present study suggest that hormone therapy with megestrol acetate has no significant role in HCC.
KW - hepatocellular carcinoma
KW - megestrol acetate
UR - http://www.scopus.com/inward/record.url?scp=0029586864&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029586864&partnerID=8YFLogxK
M3 - Article
C2 - 8804452
AN - SCOPUS:0029586864
VL - 81
SP - 351
EP - 353
JO - Tumori
JF - Tumori
SN - 0300-8916
IS - 5
ER -